ArticleCommunications biology2026
Upregulation of TCF1 and BCL11B in CD8+ effector T cells predicts favorable response to ibrutinib in patients with chronic lymphocytic leukemia.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The Bruton's kinase inhibitor ibrutinib has become a cornerstone in the treatment of chronic lymphocytic leukemia (CLL). Previous studies reported an association between upregulation of TCF1 and BCL11B transcription factors with favorable survival outcomes in CLL patients. This study aimed to investigate the correlation of TCF1 and BCL11B with response to ibrutinib. Four GEO databases were used to examine the transition of CD8 + T cell subsets and the expression of TCF1 and BCL11B in CLL patients undergoing ibrutinib treatment, and the findings were validated in a cohort of 98 CLL patients. Briefly, ibrutinib treatment increased the proportion of effector T cell-like (Teff-like) cells and upregulated TCF1 and BCL11B in CD8 + T cells. We identified a subset of TCF1 + BCL11B+ Teff-like cells with high cytotoxic activity score that were almost undetectable prior to treatment but started to emerge following ibrutinib treatment. Importantly, these changes correlated with favorable response to ibrutinib, where chromatin accessibilities of TCF7 (encoding TCF1) and BCL11B were increased and TCF1 interacted with BCL11B to restore T cell immunity, but not in patients with poor response to ibrutinib. These findings suggest that the emergence and increase of BCL11B + TCF1 + CD8+ Teff cells likely reflect reconstitution of T cell immunity induced by ibrutinib.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.